Holidays, Government shutdown?, Senate Election in Alabama, and Taxes

The government gave itself a two week extension to get some matters concluded prior to the holiday break and year end.

On Dec. 7, House and Senate lawmakers approved H.J. Res 123, a continuing resolution (CR) to fund the government through Dec. 22. The president signed the CR on Dec. 8. The CR modifies the expiration date of the previous CR (P.L. 115-56) from Dec. 8 to Dec. 22, so all provisions in the previous CR, carry forward. The two week extension is meant to provide additional time for congressional leadership to negotiate.

Many Americans are watching to see what transpires in the Senate race in Alabama. Polls open Tuesday, Dec. 12.

Regarding tax news, you may feel like you are caught in a game of hurry up and wait while the House and Senate work out their compromise tax bill. Like many Americans, you’re probably wondering what deductions will be in or out. And which tax rate you might fall under when all is said and done.

The compromise committee set up to work out the details of a unified bill aims to finish its work by December 15 and bring it to the full House for a vote during the week of December 18. The Senate is expected to vote by December 22. If a bill is passed this year—and that is looking increasingly likely--many of its provisions will take effect on January 1. (source ML news 2017)

Workshop at NIH - Adjuvant Kidney Cancer Trials

I attended a workshop at the NIH Campus in Bethesda, MD with a number of kidney cancer oncologists, surgeons, FDA representatives, National Cancer Institute staff (NCI), Society of Urologic Oncology (SUO), and several industry and patient advocates. The following is some background information:

Background:

The FDA, NCI, and SUO have agreed to joint development of a public workshop that may improve the conduct of adjuvant clinical trials in bladder cancer and kidney cancer by harmonizing definitions and management of disease recurrence. Currently, no standard definition of disease recurrence is used in these adjuvant trials. Standard practices would generate consistency and facilitate interpretation of trial results. This joint venture will enable the oncology community to combine its resources and knowledge to optimize clinical trial utility and efficiency to better serve our patients.

Goals and Objectives:

  • To standardize definitions of disease recurrence for use in bladder and kidney cancer adjuvant trials
  • To develop methods for managing disease recurrence in patients on adjuvant bladder and kidney cancer adjuvant trials
  • To discuss clinical trial and research designs with the goal of generating consistency among clinical trials in the adjuvant bladder and kidney cancer setting
  • To define common goals and methods for these adjuvant trials in the form of a potential guidance document

For more detailed information you can go here:  https://www.fda.gov/Drugs/NewsEvents/ucm574531.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

 

RESOURCE: Congressional Briefing Panelist Slide Decks

After an engaging and informative discussion at our October 12th event, we wanted to share our panelists PowerPoint slide decks. Whether you attended and want to re-visit some of the discussion points, or were not able to join us on Capitol Hill, you can find each of the four slide decks below. Many thanks to our speakers for allowing us to share their slides!

Michael B. Atkins, M.D..png

Michael B. Atkins, M.D.

Carolyn Best, PhD.png

Carolyn Best, PhD

Jay Bitkower.png

Jay Bitkower

Mohamad E. Allaf, MD.png

Mohamad Allaf, M.D.

RECAP: Congressional Briefing Event - Part 1

Thank you to all who attended the congressional briefing on Capitol Hill last Thursday, October 12th. Below are a few photos from the event. Please stay tuned here on our blog for a full recap of the event, including more photos and downloadable slide decks from each of our panelists.

 

KCAN at the Dana Farber/Harvard Cancer Center Kidney Cancer Symposium

On September 15th, KCAN joined patients, family members, caregivers, and doctors in Newton, Massachusetts at the 10th Annual Dana Farber/Harvard Cancer Center Kidney Cancer Symposium.

Our founder, Bryan Lewis, concluded the third session of the day with a presentation about KCAN's mission and goals. Click here or use the button below to watch the entire third session and see Bryan's presentation at the one hour and thirty minute mark (1:30). 

KCAN Founder Bryan Lewis speaking at the 10th Annual Dana Farber/HCC Kidney Cancer Symposium

KCAN Founder Bryan Lewis speaking at the 10th Annual Dana Farber/HCC Kidney Cancer Symposium